Related Experiment Video
Updated: Mar 15, 2026
Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
The Utility of Serum CA9 for Prognostication in Prostate Cancer
Alan D Smith1, Mathew Truong2, Rob Bristow3
1Princess Margaret Cancer Centre, Toronto, ON, Canada alan.smith@uhn.ca.
Background/Aim:
Carbonic anhydrase IX (CA9) catalyses the interconversion of carbon dioxide to carbonic acid and bicarbonate and is considered a putative biomarker of tumour hypoxia. We set out to evaluate the prognostic significance of CA9 in prostate cancer.
Patients And Methods:
Plasma samples were assessed from 68 men with high-risk localised prostate cancer treated with radical prostatectomy (RP) or radiotherapy (RT), and 20 men with castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy between 2010 and 2012 at the Princess Margaret Cancer Centre, Canada.
Results:
Of the 68 patients with high-risk localised prostate cancer, 57 underwent RP and 11 underwent RT. Baseline CA9 was not associated with recurrence or prostate-specific antigen in either group (p=0.98 and 0.20, respectively). CA9 levels before chemotherapy correlated with overall survival (r=-0.37; two-sided p=0.11).
Conclusion:
Baseline CA9 in men with CRPC may portend a more aggressive prostate cancer phenotype with poorer survival.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
08:05Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025